skip to content
  1. Home
  2. >
  3. Investment Q&A
You can view 3 more answers this month. Sign up for a free trial for unlimited access.

Investment Q&A

Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.

Q: My question is on WELL’s recent earnings report. With a revenue run rate of $300M, doesn’t this give WELL a forward-looking P/S ratio of less than 5? This sounds incredibly cheap for a high-growth, small cap company. What am I missing? Trailing revenue run rate was only $50M. Has the big jump in revenue already been priced in?
Read Answer Asked by Laxmyharan on March 22, 2021
Q: Good morning,

Could you please suggest a couple ideas for tech and health care exposure within a TFSA. I hear there are advantages/disadvantages of different type of ETFs.
Thanks
Read Answer Asked by Steven on March 18, 2021
Q: Hi Group I am presently light on Health care (GUD - HMMJ - Doc) total is 2% of my portfolio) can you suggest a couple of etfs + Stocks to balance my portfolio . I believe health care is a must own sector do you agree Thanks for your guidance
Read Answer Asked by Terence on March 18, 2021
Q: Hi, before you mentioned that we should keep small cap positions to around 3%. Ahead of WELL earnings, my WELL position is closing in on 5%. Is this reasonable or too aggressive? I can handle some volatility and I am a long term growth investor. I see in your growth portfolio WELL is over 5% now. Would you look to trim back to around 3% or maintain the 5% position? Thanks!
Read Answer Asked by Keith on March 18, 2021
Q: Hi,
I own TDOC and there is much "noise" today about Amazon entering the telehealth space and its all doom and gloom for TDOC.
I thought this news was actually "old news" in the sense that we did anticipate this was going to happen.
In your opinion, does this move by Amazon fundamentally change anything for TDOC?
Thanks,
Read Answer Asked by ilie on March 18, 2021
Q: Retired, dividend-income investor. I am in the process of trimming my way out of Shaw (held in my TFSA) and looking at where to deploy the funds as they become available over time. I know WELL is not the same risk as SJR, but I am considering it.

However I really focus on asset allocation. I see WELL listed as Healthcare as well as Technology. Is it a hybrid? My tracking system has no problem with splitting it up into either or both sectors. As an example TC Energy, as a pipeline, is categorized as both a Utility as well as Energy. I believe it is a Utility, but because it seems to trade more like Energy stocks. I go 50-50.

I could do the same with WELL. What portion of their business is technology? Is any part of their business related to the Telecom sector? If I was forced to pick one sector, I'd go with Healthcare. Your thoughts?

Thanks....Steve
Read Answer Asked by Stephen on March 17, 2021
Q: Good morning, would you be able to comment on NovaBay Pharmaceuticals, do you see it as a stock worth picking up, and if you do, at what entry point would you yourself feel comfortable going in? I have been waiting for it to go lower but it seems to have a good bit of strength in the .90-$1.00 range. I was hoping it would dip into the .70s but its not looking like that will happen again soon. Thank you!!
Read Answer Asked by dennis on March 15, 2021
Q: Haven’t seen a question since January. MDRA looks over sold and the stock has just issued a possible early technical buy signal using scholastics. More importantly this mRNA technology got another “shot in the arm” with the latest data indicting that they may work by STOPPING transmission not just mounting an immune response to decrease the course f the disease while you remain contagious. How well funded is MRNA. How is their free cash flow and their debt load. This technology keeps getting more and more exciting. Malaria, the common cold, HIV, etc!! And if is better maybe even influenza?
For the science geeks: Impact of the COVID-19 Vaccine on Asymptomatic Infection Among Patients Undergoing Pre-Procedural COVID-19 Molecular Screening
Aaron J Tande, MD, Benjamin D Pollock, PhD, MSPH, Nilay D Shah, PhD, Gianrico Farrugia, MD, Abinash Virk, MD, Melanie Swift, MD, MPH, Laura Breeher, MD, MPH, Matthew Binnicker, PhD, Elie F Berbari, MD Author Notes
Clinical Infectious Diseases, ciab229, https://doi.org/10.1093/cid/ciab229
Published: 10 March 2021
Read Answer Asked by Paul on March 15, 2021
Q: So working in the finance industry, when it comes to business valuation, I know private health clinics get very low multiples. If Well is continues to consolidate in a space where now one else is and provides technological efficiencies. Even if they are just able to capture the majority of market share in Canada, could the potential upside be the sky?
Read Answer Asked by James on March 11, 2021
Looking for more? Sign up for a FREE 14 day trial! No credit card required

We invite you to sign up for a 14 day free trial of 5i Research!
Experience all the benefits and tools we have to offer; stock research, model portfolios, Q&A with our experts, and so much more. Join a community of like-minded investors today!